From LSD To GD To PD

Multiple companies are currently trying to find new and better ways to treat inherited lysosomal storage disorders (LSD), which are responsible for more than fifty rare and orphan diseases. Although Type 1 GD is the most common LSD and doesn’t generally involve the central nervous system (CNS), most LSDs do, including Hunter syndrome (MPS II), Tay Sachs disease, and Niemann-Pick disease, type C. Several companies are looking for new ways to treat LSD symptoms in the CNS, and, if possible, to find ways to extend the agents to PD. Among them, ArmaGen Technologies Inc. uses its protein-fusion technology to get large molecule agents into the brain that otherwise would not transit the blood-brain barrier. ArmaGen’s lead drug candidates focus on CNS therapies for LSDs that include MPS I and II, but it also has an early-stage agent in its pipeline, AGT-190, that targets PD. Deploying a related “Trojan horse” platform technology for getting large molecules into the brain, Angiochem Inc. struck a deal in 2012 potentially worth more than $300 million with $31.5 million in up-front cash, with GlaxoSmithKline PLC, for LSD-targeting fusion agents that could reach into the brain. Although the partnership is focused on rare LSDs, it may, according to news reports, eventually extend to PD. [See Deal]

A few smaller companies have set their sights on PD. Three are using synuclein-antibody strategies as active or passive vaccines:...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

Final Chance To Have Your Say: Take Scrip's Reader Survey This Week

 

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access Scrip, or if you love it how it is, now is the time to have your voice heard.

Galapagos Expands Point-Of-Care CAR-T Study To The US

 

CEO Paul Stoffels said gaining US clearance for an IND for its novel CAR-T product was demanding, but now opens up a pathway towards a pivotal study starting in 2025.

Analysts Split On Eisai’s Chances Of Changing EU Regulator’s Mind On Leqembi

 

A final rejection of Leqembi could also spell the same fate for Lilly’s rival drug but public outcry and demand for Alzheimer’s therapies might force the regulator’s hand

More from Scrip

Compass Pathways’ Antidepressant Advances In An Increasingly Tough Psychedelic Market

 
• By 

Psychedelics appear to be in vogue after years of being relegated to alternative medicine. But investor pushback after the highly anticipated release of Phase III trial data by Compass Pathways reveals an increasingly high bar for development.

Eolo Pharma Advances In Obesity With Thermogenesis Approach

 
• By 

Emerging Company Profile: Early-stage biotech Eolo will seek cash and deals for its novel obesity drug SANA after positive Phase I results for weight loss, lean muscle mass preservation and fat mass reduction.

BioMarin’s Roctavian Continues to Shine In Hemophilia A Despite Commercial Woes

 

Roctavian shows durable bleed control and safety over five years, but high costs and access hurdles limit its commercial outlook.